Clinical Research Directory
Browse clinical research sites, groups, and studies.
Single-dose,First-in-human of KLA478
Sponsor: Hunan Kelun Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to evaluate the safety and tolerability and pharmacokinetics of single doses of KLA478 in healthy volunteers;
Official title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of KLA478 in Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-11-26
Completion Date
2026-09-30
Last Updated
2026-02-27
Healthy Volunteers
Yes
Conditions
Interventions
pramipexole hydrochloride sustained-release tablets
P.O., single dose
KLA478
intramuscular injection, single dose
placebo
intramuscular injection, single dose
Locations (1)
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China